Navigation Links
California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
Date:1/22/2013

100 Best-Performing CEOs in the World” in both 2009 (ranked #50) and 2013 (ranked #26) and was recognized as the “No. 1 CEO in Specialty Pharmaceuticals” by Institutional Investor magazine in 2005, 2007, and 2012. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology. He holds a law degree from the Europa Institute at the University of Amsterdam, a master’s degree from the University of Edinburgh, and a master of business administration from the London Business School.

Pyott replaces outgoing CHI Chairman Carl Hull, senior vice president and general manager of diagnostics at Hologic + Gen-Probe Inc. Hull served as chairman from 2011-2012 and has been a dedicated board member since July 2009.

Gregory joined Genzyme Corporation, a Sanofi company, in 1989, where he was responsible for a number of discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation of CFTR. This research on the molecular basis of cystic fibrosis led to the development of Genzyme’s CF gene therapy program, for which Gregory was project team leader until 1993. From 1993 to 1995, he served as director of molecular biology at Canji, Inc. in San Diego, where he developed therapeutics based on tumor suppressor genes. Gregory returned to Genzyme in 1995 to head the gene therapy program as vice president. In 2003, Gregory was appointed head of research for Genzyme, where he was responsible for early R&D, from discovery to development, in all therapeutic areas. In 2011, following the acquisition of Genzyme by Sanofi, Gregory was appointed head of the Sanofi-Genzyme R&D Center. In his current role, he is responsible for R&D, from discovery through proof of concept in man, in a wide range of therapeutic areas, including rare d
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
4. Agendia Signs Contract with Blue Shield of California
5. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
6. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
7. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
8. Lightning Brewery’s Craft Beer Old Tempestuous Ale Wins Best of Show at 2012 California State Fair Commercial Brewing Competition
9. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
10. California Healthcare Institute Issues Statement on Supreme Court Ruling on the Affordable Care Act
11. California Physical Therapists Prediction Proved "Right" by Results of State Board Audit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly traded ... development, sales and marketing of premium branded highly ... it is awarding exclusive Vestiage territories in the ... Illuminating Facial Care. Qualified applicants can request an ... to info(at)vestiageinc(dot)com and putting RELUMA in the "Subject" ...
(Date:5/23/2013)... 2013  BioScrip, Inc. (NASDAQ: BIOS ) ... Jefferies 2013 Global Healthcare Conference to be held June ... Richard Smith , President and ... , Chief Financial Officer, will present on Monday, June ... About BioScrip BioScrip, Inc. provides comprehensive ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... by the National Nanotechnology Initiative (NNI) and the Oregon ... landscape of regional, state, and local (RSL) nanotechnology initiatives. ... visits on April 30 Where: Portland, Oregon ... Street, Portland, OR Who: Leaders of regional, ...
... PML Consortium, an association of pharmaceutical and biotechnology companies, ... from BioFortis to share and manage data relating to ... adverse event. Progressive multifocal leukoencephalopathy (PML) is ... immunocompromised patients. PML has been identified as a known ...
... about the disease and its overall occurrence and progression ... market. This is being exacerbated by the limited availability ... need for innovative and enhanced therapeutic and diagnostic tools ... treatment options. New analysis from Frost & ...
Cached Biology Technology:Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... State University have essentially "cured" laboratory mice of mild, ... enzyme. The findings could offer a new approach ... could be identified that would do the same thing, ... Increased levels of this enzyme, called fatty acid ...
... mechanism for regulating viruses that has worked its way ... between adult and fetal hemoglobin production, Medical College of ... key to more targeted therapies for sickle cell patients ... oxygen throughout the body. Fetal hemoglobin, on the ...
... Malolactic fermentation is a key part in the process ... a common component in fruit, undergoes a chemical transformation, ... natural cider (unlike with wine), after this process there ... that the lactic bacteria become the dominant microbiota. Some ...
Cached Biology News:Discovery points to new approach for diabetes therapy 2Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3Thesis analyzes factors responsible for the case of Basque natural cider turning bitter 2
... an intracellular marker normally present at high ... of bone marrow prelymphocytes. Elevated levels of ... cells are found to be associated with ... TdT thus provides a useful adjunct in ...
Request Info...
... RapidStak is a fast and ... Its high capacity and reliable ... confident walk away time than typical ... of set-up make for a seamless ...
... Interacting Protein/PBIP1 (phospho T78) ( Abpromise ... Antigen: Synthetic peptide: ... of Human MLF1 Interacting Protein ... 359815 Swiss Protein ...
Biology Products: